Suven Life Sciences Limited · NSE:SUVEN
Suven Life Sciences — Q2 FY2019 Earnings Presentation
13 slides from Suven Life Sciences's earnings presentation, Nov 14, 2018
Slide 1: SUVEN Life Sciences Ltd - Communication to investors
SUVEN Life Sciences Ltd Communication to investors September 2018 14-Nov-18 2018-19 Q2 results
Slide 2: Risk statement
Risk statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Financial Quick View
FINANCIAL QUICK VIEW Q2-FY19 vs Q2- FY 2018-19 FY18 YoY (6 months) Growth in revenue -14.18% 14.41% Growth in PAT -43.45% -7.44% Growth in EBIDTA -38.16% -3.64% Growth in Pre-R&D EBIDTA -29.78% -2.31% Increase in R&D Costs 6.23% 2.54% R&D to sales 8.00% 9.59% 14-Nov-18 2018-19 Q2 results
Slide 4: Major Profitability Ratios
MAJOR PROFITABILITY RATIOS Q2 Sep 19 HY Sep 19 PAT to Income 18.67% 19.17% EBIDTA to 32.26% 32.90% Income Cash Flow to 24.45% 22.91% Income Pre-R&D EBITDA 45.15% 42.49% to Income 14-Nov-18 2018-19 Q2 results
Slide 5: Q2 to Q1 Comparison
Q2 to Q1 COMPARISON Revenue - INR Million PAT - INR Million 2,100.00 1,997.90 500.00 387.73 400.00 1,600.00 300.00 1,100.00 961.08 179.41 200.00 600.00 100.00 100.00 - Q1 Jun 18 Q2 Sep 18 Q1 Jun 18 Q2 Sep 18 EBIDTA - INR Million Pre-R&D EBIDTA - INR Million 750.00 880.00 823.47 663.59 650.00 780.00
Slide 6: Revenue Comparison
REVENUE COMPARISON INR Million 3,500.00 2,958.98 3,000.00 2,586.33 2,500.00 2,000.00 1,500.00 1,119.91 961.08 1,000.00 500.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 14-Nov-18 2018-19 Q2 results
Slide 7: PAT Comparison
PAT COMPARISON INR Million 700.00 612.69 600.00 567.13 500.00 400.00 317.23 300.00 200.00 179.41 100.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 14-Nov-18 2018-19 Q2 results
Slide 8: EBIDTA Comparison
EBIDTA COMPARISON INR Million 1,200.00 1,010.38 1,000.00 973.60 800.00 600.00 501.28 400.00 310.01 200.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 2018-19 Q2 results 14-Nov-18
Slide 9: R & D – Expenditure
R & D – EXPENDITURE INR Million 300.00 283.76 276.73 250.00 200.00 150.00 123.87 116.61 100.00 50.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 2018-19 Q2 results 14-Nov-18
Slide 10: Pre-R&D EBIDTA
PRE-R&D EBIDTA INR Million 1,400.00 1,287.11 1,257.36 1,200.00 1,000.00 800.00 617.89 600.00 433.88 400.00 200.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 2018-19 Q2 results 14-Nov-18
Slide 11: Pre-R&D Cashflow
PRE-R&D CASHFLOW INR Million 1,200.00 994.74 1,000.00 961.58 800.00 600.00 487.24 400.00 358.88 200.00 - Q2 Sep 17 Q2 Sep 18 HY Sep 17 HY Sep 18 2018-19 Q2 results 14-Nov-18
Slide 12: Financial Snapshot
FINANCIAL SNAPSHOT All figures are in INR Million, other than ratios and EPS 2018-19 2018-19 Growth 2017-18 Growth 2018-19 2017-18 Growth Q2 Q1 % Q2 % HY HY % Income 961.08 1,997.90 -51.90% 1,119.91 -14.18% 2,958.98 2,586.33 14.41% Pre-R&D EBITDA 433.88 823.47 -47.31% 617.89 -29.78% 1,257.36 1,287.1
Slide 13: News Release
News Release • During the period Suven secures 12 product patents covering Australia, Canada, China, Eurasia, Hong Kong, Israel, Japan, New Zealand, Sri Lanka and USA. • Updates on CRAMS projects: Total – 116; Phase 1 – 76, Phase 2 – 35, Phase 3 – 1 and commercial – 4. • Suven presented at 11th Clin
Suven Life Sciences — Q2 FY2019 Earnings Presentation on 6ix